Seres Therapeutics Inc
Biopharmaceutical company developing living therapeutics based on its Microbiome program
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Seres Therapeutics stock with a target price of $4.06, indicating potential growth.
Financial Health
Seres Therapeutics shows strong financial performance with solid cash flow and book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring MCRB
MASH Drug Developers Could Attract M&A in 2025
Roche's $3.5 billion deal to acquire 89bio for its late-stage liver disease drug highlights the immense commercial potential seen in the MASH treatment landscape. This move could trigger a wave of investment and further acquisitions, benefiting other biotech firms with promising therapies for metabolic disorders.
Published: September 19, 2025
Explore BasketMASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: September 18, 2025
Explore BasketMicrobiome Modulators
Discover a carefully selected group of innovative biotechnology companies leveraging the untapped power of the body's microbiome. These pioneering firms are creating revolutionary therapies that target the root causes of disease by rebalancing our internal microbial ecosystems.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Ahead
Pipeline news and trial readouts can move the stock substantially, though outcomes are uncertain and may not lead to commercial success.
Microbiome Opportunity
Interest in microbiome therapeutics is growing as a new modality for GI and systemic conditions, but scientific and regulatory hurdles remain.
High Risk, High Uncertainty
Small market cap and limited revenues mean financing needs and binary outcomes are likely; consider suitability and seek professional advice where needed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
